Industrial / General / Biotech / BioTech / Environment / Boston blog main / Boulder / Denver blog main / Detroit blog main / Europe blog main / Indiana blog main / National / National blog main / New York blog main / Raleigh-Durham blog main / San Diego blog main / San Diego top stories / Seattle blog main / Texas blog main / Wisconsin blog main / Avalon Ventures / BridgeBio Pharma / Bruce Steel / clinical trials / COI Pharmaceuticals / Compugen / convertible bonds / coronavirus / COVID-19 / debt / Equillium / equity / Financing / fundraising / Greg Dombal / Halloran Consulting Group / Imara / IPO / Jay Lichter / Kala Pharmaceuticals / Keros Therapeutics / Life Sciences / Nanostring Technologies / Pandemic

Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown

Posted On: Mar 24, 2020   |   Posted By: Xconomy

Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown

The coronavirus pandemic is narrowing the avenues open to biotechs for financing their endeavors, according to some industry veterans. “I think that fear of losing out has pretty much gone out the window right now,” said Equillium CEO Bruce Steel in a phone interview with Xconomy, speaking generally of investor appetite. “I think they're going to be very patient and pick their spots in terms of where they're going to invest, and that's going to put a lot of pressure on companies. If you map that backdrop of the overall investment environment against the backdrop where companies may...

Continue reading ...